Abstract
Leishmaniasis is a neglected tropical disease caused by Leishmania parasites and is associated to more than 1.3 million cases annually. Some of the pharmacological options for treating the disease are pentavalent antimonials, pentamidine, miltefosine, and amphotericin B. However, all are associated with a wide range of adverse effects and contraindications, as well as resistance from the parasite. In the present study, we looked for pharmacological alternatives to treat leishmaniasis, with a focus on drug repurposing. This was done by detecting potential homologs between proteins targeted by approved drugs and proteins of the parasite. The proteins were analyzed using an interaction network, and the drugs were subjected to in vitro evaluations and pharmacokinetics simulations to compare probable plasma concentrations with the effective concentrations detected experimentally. This strategy yielded a list of 33 drugs with potential anti-Leishmania activity, and more than 80 possible protein targets in the parasite. From the drugs tested, two reported high in vitro activity (perphenazine EC50 = 1.2 µg/mL and rifabutin EC50 = 8.5 µg/mL). These results allowed us to propose these drugs as candidates for further in vivo studies and evaluations of the effectiveness on their topical forms.
Similar content being viewed by others
References
WHO, “Leishmaniasis Technical Report,” 2010.
Alvar J et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7:5
Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5(3):150–158
Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 5(6):485–497
Chakravarty J, Sundar S (2010) Drug resistance in leishmaniasis. J Glob Infect Dis 2(2):167–176
Adams CP, Van Brantner V (2006) Market watch : estimating the cost of new drug development—is it really $802 million? Health Aff 25(2):420–428
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673–683
Ekins S, Williams, AJ, Krasowski MD, Freundlich JS (2011) In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 16(7–8):298–310
Novac N (2013) Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 34(5):267–272
Czock D, Markert C, Hartman B, Keller F (2009) Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol 5(5):475–487
Villoutreix BO, Lagorce D, Labbé CM, Sperandio O, Miteva MA (2013) One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov Today 18(21–22):1081–1089
Flórez AF et al (2010) Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection. BMC Bioinform 11:484
Scardoni G and Laudanna C (2012) Network centralities for Cytoscape Centralities. Bioinformatics, pp 1–8
Taylor VM et al (2011) In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis. Antimicrob Agents Chemother 55(10):4755–4764
Pulido SA (2012) Acta Tropica Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Trop 122:36–45
Finney DJ (1952) Statistical method in biological assay. Stat Method Biol Assay 172:533–534
Schumitzky A, Wang X, D’Argenio DZ (2009) ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
Dorlo TPC et al (2008) Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52(8):2855–2860
Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD (1999) The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Chemotherapy 45(9):48–53
Travi B, Osorio Y (1998) Failure of albendazole as an alternative treatment of Cutaneous leishmaniasis in the hamster model. Mem Inst Oswaldo Cruz 93(4):515–516
Khan I, Yasmin R, Sidiqui I (2007) Chloroquine in cutaneous leishmaniasis. J Pakistan Assoc Dermatologists 17(2):95–100
Behforouz NC, Wenger CD, Mathison BA (1986) Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major. J Immunol 136(8):3067
Werbovetz KA, Brendle JJ, Sackett DL (1999) Purification, characterization, and drug susceptibility of tubulin from Leishmania. Mol Biochem Parasitol 98(1):53–65
Cunningham AC (2002) Parasitic adaptive mechanisms in infection by Leishmania. Exp Mol Pathol 72(2):132–141
Burchmore RJS, Barrett MP (2001) Life in vacuoles—nutrient acquisition by Leishmania amastigotes. Int J Parasitol 31(12):1311–1320
Chawla B, Madhubala R (2010) Drug targets in Leishmania. J Parasit Dis 34(1):1–13
A. K. Mishra et al. (2017) Discovery of novel inhibitors for Leishmania nucleoside diphosphatase kinase (NDK) based on its structural and functional characterization. J. Comput Aided Mol Des 0(0):0
Patino LH et al (2017) Spatial distribution, Leishmania species and clinical traits of Cutaneous leishmaniasis cases in the Colombian army. PLoS Negl Trop Dis 11(8):e0005876
Mazumder S, Mukherjee T, Ghosh J (1992) Allosteric modulation of Leishmania donovani plasma membrane Ca (2+)-ATPase by endogenous calmodulin. J Biol 267:18440–18446
Folgueira C, Carrión J, Moreno J, Saugar JM, Cañavate C, Requena JM (2008) Effects of the disruption of the HSP70-II gene on the growth, morphology, and virulence of Leishmania infantum promastigotes. Int Microbiol 11(2):81–89
Chavali AK, Blazier AS, Tlaxca JL, Jensen PA, Pearson RD, Papin JA (2012) Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst Biol 6(1):27
Rodriguez-contreras D, Feng X, Keeney KM, Bouwer HGA, Landfear SM (2007) Phenotypic characterization of a glucose transporter null mutant in Leishmania Mexicana 153:9–18
Ursu O et al (2017) DrugCentral: online drug compendium. Nucleic Acids Res 45:D932–D939
Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR (2010) Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 50(1):73–80
Baheti G, Kiser JJ, Havens PL, Fletcher CV (2011) Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother 55(11):5294–5299
Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, Timmins P, Graham GG, Furlong TJ, Greenfield JR, Williams KM, Day RO (2013) Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 52(5):373–384
Moore KHP, Yuen GJ, Hussey EK, Pakes GE, Eron JJ, Bartlett JA (1999) Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 43(12):3025–3029
Lindemalm S, Savic RM, Karlsson MO, Juliusson G, Liliemark J, Albertioni F (2005) Application of population pharmacokinetics to cladribine. BMC Pharmacol 5:4
Gatti G, Papa P, Torre D, Andreoni M, Poggio A, Bassetti M, Marone P (1998) Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 42(8):2017–2023
Acknowledgements
This Project was funded by the Departamento Administrativo de Ciencia y Tecnología e Innovación-Colciencias, under the contract number 534–2013 and Project code 1115–569-33419. The authors acknowledge Dr. Andres Zuluaga and Dr. Carlos Rodriguez for their support and advisory in the pharmacokinetic analysis, and Professor Jaime Hincapie for his collaboration in the study design.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We declare that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bustamante, C., Ochoa, R., Asela, C. et al. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations. J Comput Aided Mol Des 33, 845–854 (2019). https://doi.org/10.1007/s10822-019-00230-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-019-00230-y